canakinumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
human origin 4952 914613-48-2

Description:

MoleculeDescription

Synonyms:

  • canakinumab
  • ilaris
  • ACZ885
a human anti-interleukin-1beta monoclonal antibody for treatment of cryopyrin-associated periodic syndrome
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
2.70 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
June 17, 2009 FDA NOVARTIS PHARMS
Oct. 23, 2009 EMA
Sept. 26, 2011 PMDA Novartis Pharma K.K.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Inappropriate schedule of product administration 878.16 17.85 412 11165 149521 90467349
Haemophagocytic lymphohistiocytosis 429.64 17.85 133 11444 15326 90601544
Pyrexia 364.89 17.85 433 11144 660052 89956818
Incorrect dose administered 195.30 17.85 123 11454 78807 90538063
Serum ferritin increased 137.76 17.85 47 11530 7334 90609536
Interleukin level increased 132.17 17.85 28 11549 694 90616176
Clubbing 118.38 17.85 24 11553 476 90616394
Condition aggravated 116.50 17.85 243 11334 595302 90021568
Illness 114.35 17.85 90 11487 81879 90534991
Serum amyloid A protein increased 109.76 17.85 24 11553 693 90616177
Growth retardation 106.99 17.85 28 11549 1755 90615115
COVID-19 99.42 17.85 115 11462 168728 90448142
Epidural lipomatosis 89.16 17.85 17 11560 242 90616628
Hypertensive cardiomyopathy 86.44 17.85 17 11560 287 90616583
Cellulitis staphylococcal 67.28 17.85 17 11560 926 90615944
Short stature 65.15 17.85 17 11560 1053 90615817
Cushingoid 64.89 17.85 30 11547 10365 90606505
Lymphadenopathy 63.23 17.85 50 11527 45725 90571145
Interstitial lung disease 58.83 17.85 60 11517 76345 90540525
Actinomycotic sepsis 58.72 17.85 12 11565 248 90616622
Symptom recurrence 57.78 17.85 21 11556 3938 90612932
Juvenile idiopathic arthritis 53.98 17.85 20 11557 3957 90612913
Hepatosplenomegaly 51.64 17.85 18 11559 2991 90613879
Blood lactate dehydrogenase increased 50.87 17.85 35 11542 25897 90590973
Herpes zoster infection neurological 49.83 17.85 12 11565 535 90616335
Concomitant disease aggravated 47.31 17.85 25 11552 11493 90605377
Malaise 46.36 17.85 172 11405 585814 90031056
Focal nodular hyperplasia 45.72 17.85 12 11565 760 90616110
Cough 42.37 17.85 123 11454 368839 90248031
Drug reaction with eosinophilia and systemic symptoms 41.22 17.85 38 11539 42720 90574150
Epstein-Barr virus infection 41.21 17.85 22 11555 10322 90606548
C-reactive protein increased 41.20 17.85 79 11498 181310 90435560
Infusion related reaction 38.99 17.85 4 11573 416776 90200094
Chemokine increased 38.77 17.85 6 11571 21 90616849
Gastroenteritis 38.38 17.85 31 11546 29198 90587672
Graft versus host disease in gastrointestinal tract 38.19 17.85 16 11561 4372 90612498
Influenza 37.11 17.85 65 11512 139199 90477671
Arthralgia 36.84 17.85 196 11381 778326 89838544
Varicella zoster virus infection 36.67 17.85 15 11562 3862 90613008
Pneumonia lipoid 34.61 17.85 7 11570 137 90616733
Tonsillitis 34.04 17.85 17 11560 6952 90609918
Vitiligo 33.83 17.85 12 11565 2098 90614772
Autoimmune thyroiditis 33.67 17.85 16 11561 5877 90610993
Product supply issue 33.24 17.85 13 11564 2979 90613891
Chondrocalcinosis 33.15 17.85 11 11566 1574 90615296
Steroid dependence 32.98 17.85 12 11565 2257 90614613
Secondary adrenocortical insufficiency 32.73 17.85 12 11565 2306 90614564
Growth failure 32.70 17.85 8 11569 381 90616489
Hyperplasia 32.58 17.85 10 11567 1114 90615756
Systemic lupus erythematosus 32.52 17.85 4 11573 361892 90254978
Spinal fracture 32.46 17.85 25 11552 21991 90594879
Oropharyngeal pain 32.30 17.85 55 11522 115132 90501738
Rash 32.07 17.85 192 11385 795908 89820962
Pharyngitis streptococcal 31.81 17.85 20 11557 12722 90604148
Spondyloarthropathy 31.74 17.85 10 11567 1214 90615656
Drug hypersensitivity 31.54 17.85 10 11567 463599 90153271
Drug resistance 31.18 17.85 28 11549 30421 90586449
Obliterative bronchiolitis 31.03 17.85 12 11565 2669 90614201
Rhinorrhoea 29.99 17.85 46 11531 88270 90528600
Autoinflammatory disease 29.61 17.85 7 11570 288 90616582
SARS-CoV-2 test positive 29.13 17.85 18 11559 11110 90605760
Ileal ulcer 28.86 17.85 9 11568 1057 90615813
Synovitis 28.77 17.85 4 11573 329748 90287122
Immune thrombocytopenia 28.55 17.85 19 11558 13307 90603563
Blood creatine phosphokinase decreased 28.02 17.85 8 11569 694 90616176
Disease recurrence 27.94 17.85 29 11548 37624 90579246
Abdominal pain 27.81 17.85 112 11465 395609 90221261
Product storage error 27.71 17.85 22 11555 20219 90596651
Product use in unapproved indication 27.60 17.85 100 11477 336136 90280734
Amyloidosis 27.41 17.85 9 11568 1247 90615623
Hepatic steatosis 26.60 17.85 28 11549 36917 90579953
Arthropathy 26.56 17.85 7 11570 366235 90250635
Cutaneous symptom 25.63 17.85 7 11570 516 90616354
Alopecia 25.35 17.85 16 11561 495055 90121815
Cryopyrin associated periodic syndrome 25.06 17.85 7 11570 561 90616309
Drug ineffective for unapproved indication 24.45 17.85 36 11541 66608 90550262
Acute graft versus host disease in skin 24.41 17.85 12 11565 4744 90612126
Bacterial sepsis 23.95 17.85 12 11565 4943 90611927
Familial cold autoinflammatory syndrome 23.90 17.85 3 11574 0 90616870
Graft versus host disease in skin 23.67 17.85 11 11566 3842 90613028
Periodontal inflammation 23.43 17.85 4 11573 29 90616841
Syringe issue 23.27 17.85 11 11566 3991 90612879
Osteoporosis 23.08 17.85 43 11534 96488 90520382
Fall 22.76 17.85 17 11560 481793 90135077
Lymphocyte count decreased 22.49 17.85 25 11552 35025 90581845
Cytopenia 21.84 17.85 18 11559 17431 90599439
Hepatomegaly 21.56 17.85 16 11561 13310 90603560
Abdominal discomfort 21.09 17.85 18 11559 477310 90139560
Hypoaesthesia 20.96 17.85 7 11570 314203 90302667
Upper respiratory tract inflammation 20.79 17.85 9 11568 2663 90614207
Asteatosis 20.72 17.85 4 11573 61 90616809
Viral infection 20.71 17.85 26 11551 41388 90575482
Clostridium difficile colitis 20.59 17.85 21 11556 26685 90590185
Exposure during pregnancy 20.54 17.85 3 11574 238407 90378463
Type IV hypersensitivity reaction 20.43 17.85 10 11567 3916 90612954
Familial mediterranean fever 20.42 17.85 4 11573 66 90616804
Discomfort 20.35 17.85 5 11572 274330 90342540
Faecal calprotectin increased 20.29 17.85 10 11567 3977 90612893
Pharyngitis 20.17 17.85 19 11558 21928 90594942
Spinal stenosis 19.80 17.85 17 11560 17407 90599463
Wound 19.78 17.85 7 11570 302973 90313897
Splenomegaly 19.76 17.85 15 11562 12909 90603961
Nasal congestion 19.75 17.85 37 11540 83377 90533493
Rheumatoid arthritis 19.56 17.85 11 11566 362603 90254267
Gastrointestinal perforation 19.50 17.85 10 11567 4322 90612548
Sputum abnormal 18.71 17.85 6 11571 771 90616099
Quality of life decreased 18.62 17.85 14 11563 11875 90604995
Hyperferritinaemia 18.24 17.85 5 11572 374 90616496
Failure to thrive 18.04 17.85 12 11565 8399 90608471
Alveolar proteinosis 18.01 17.85 6 11571 870 90616000

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Apparent death 1023.97 26.90 231 11541 3477 42606086
Diverticulitis 679.46 26.90 250 11522 22523 42587040
Joint swelling 460.39 26.90 266 11506 67756 42541807
Pulmonary thrombosis 389.11 26.90 128 11644 8220 42601343
Red blood cell sedimentation rate increased 379.00 26.90 131 11641 9793 42599770
Inappropriate schedule of product administration 374.23 26.90 265 11507 95637 42513926
Deep vein thrombosis 369.96 26.90 242 11530 76715 42532848
Terminal state 311.50 26.90 93 11679 4330 42605233
Pulmonary embolism 305.41 26.90 257 11515 119355 42490208
C-reactive protein abnormal 254.95 26.90 96 11676 9165 42600398
Renal failure 253.50 26.90 251 11521 143475 42466088
Pain 244.60 26.90 318 11454 244530 42365033
C-reactive protein increased 179.40 26.90 145 11627 63415 42546148
Photosensitivity reaction 161.48 26.90 76 11696 12626 42596937
Haemophagocytic lymphohistiocytosis 160.57 26.90 85 11687 18137 42591426
Intestinal sepsis 160.27 26.90 38 11734 713 42608850
Joint arthroplasty 155.30 26.90 39 11733 938 42608625
Thrombosis 153.73 26.90 137 11635 68374 42541189
Arthropathy 122.46 26.90 85 11687 29512 42580051
Drug ineffective 121.28 26.90 414 11358 629783 41979780
Growth retardation 116.08 26.90 38 11734 2394 42607169
Contraindicated product administered 105.53 26.90 73 11699 25199 42584364
Pyrexia 104.46 26.90 290 11482 393752 42215811
Short stature 103.00 26.90 24 11748 416 42609147
Herpes zoster 101.83 26.90 85 11687 38792 42570771
Sepsis 90.15 26.90 181 11591 199153 42410410
Intentional product use issue 90.11 26.90 105 11667 71728 42537835
Interstitial lung disease 89.07 26.90 109 11663 78353 42531210
Stent placement 86.86 26.90 38 11734 5322 42604241
Illness 83.48 26.90 63 11709 24867 42584696
Stomatitis 83.03 26.90 85 11687 50244 42559319
Feeling abnormal 74.46 26.90 94 11678 69692 42539871
Knee arthroplasty 71.81 26.90 39 11733 8742 42600821
Spinal instability 70.87 26.90 19 11753 594 42608969
Urticaria 70.07 26.90 94 11678 73942 42535621
Cushingoid 67.86 26.90 28 11744 3394 42606169
Incorrect dose administered 65.67 26.90 77 11695 52897 42556666
Serum amyloid A protein increased 59.27 26.90 14 11758 258 42609305
Drug interaction 58.30 26.90 4 11768 266995 42342568
Juvenile idiopathic arthritis 57.14 26.90 23 11749 2616 42606947
Drug intolerance 55.54 26.90 88 11684 80336 42529227
Cellulitis 53.43 26.90 75 11697 61510 42548053
Toxicity to various agents 51.30 26.90 3 11769 229133 42380430
Muscle abscess 50.14 26.90 16 11756 928 42608635
Myocardial infarction 47.09 26.90 105 11667 123904 42485659
Pneumonia streptococcal 44.23 26.90 17 11755 1711 42607852
Nausea 43.67 26.90 28 11744 396771 42212792
Off label use 40.88 26.90 308 11464 638027 41971536
Osteopenia 40.82 26.90 24 11748 6254 42603309
Interleukin level increased 38.56 26.90 13 11759 897 42608666
Secondary adrenocortical insufficiency 37.67 26.90 16 11756 2083 42607480
Tonsillitis 36.37 26.90 17 11755 2774 42606789
Drug hypersensitivity 35.31 26.90 82 11690 99307 42510256
Condition aggravated 34.59 26.90 153 11619 260601 42348962
Hypotension 34.54 26.90 14 11758 257617 42351946
Vein disorder 34.37 26.90 15 11757 2087 42607476
Atlantoaxial instability 34.21 26.90 10 11762 431 42609132
Osteoporosis 33.73 26.90 30 11742 14876 42594687
Arthritis 33.20 26.90 49 11723 42016 42567547
Acute kidney injury 32.74 26.90 32 11740 367305 42242258
Hand fracture 32.69 26.90 16 11756 2890 42606673
Autoinflammatory disease 32.59 26.90 7 11765 82 42609481
Dyspnoea 32.53 26.90 45 11727 442576 42166987
Haemoglobin decreased 30.48 26.90 93 11679 132378 42477185
Secondary amyloidosis 29.24 26.90 7 11765 137 42609426
Foot fracture 28.47 26.90 19 11753 6172 42603391
Arthritis infective 27.49 26.90 16 11756 4090 42605473
Inflammatory marker increased 26.97 26.90 19 11753 6737 42602826

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Inappropriate schedule of product administration 593.76 18.65 383 17469 203254 110368193
Apparent death 453.25 18.65 103 17749 2799 110568648
Haemophagocytic lymphohistiocytosis 414.65 18.65 165 17687 31394 110540053
Pyrexia 359.01 18.65 569 17283 897696 109673751
Pulmonary thrombosis 321.01 18.65 110 17742 13753 110557694
Terminal state 296.78 18.65 84 17768 5583 110565864
Diverticulitis 239.69 18.65 133 17719 53389 110518058
Incorrect dose administered 200.66 18.65 152 17700 103489 110467958
Red blood cell sedimentation rate increased 200.18 18.65 136 17716 78166 110493281
C-reactive protein increased 156.23 18.65 184 17668 217735 110353712
Serum amyloid A protein increased 144.72 18.65 33 17819 909 110570538
Intestinal sepsis 137.33 18.65 32 17820 972 110570475
Interstitial lung disease 137.04 18.65 139 17713 139195 110432252
Growth retardation 129.44 18.65 37 17815 2545 110568902
Illness 125.73 18.65 105 17747 82066 110489381
Thrombosis 122.84 18.65 117 17735 108545 110462902
Photosensitivity reaction 118.37 18.65 65 17787 25524 110545923
Interleukin level increased 98.47 18.65 27 17825 1594 110569853
Sepsis 95.15 18.65 181 17671 327165 110244282
Joint arthroplasty 93.42 18.65 31 17821 3506 110567941
Deep vein thrombosis 91.77 18.65 113 17739 139774 110431673
Pulmonary embolism 89.14 18.65 139 17713 214335 110357112
Condition aggravated 83.34 18.65 284 17568 734552 109836895
Juvenile idiopathic arthritis 80.89 18.65 32 17820 5975 110565472
Clubbing 80.87 18.65 20 17832 785 110570662
Serum ferritin increased 80.54 18.65 39 17813 11808 110559639
Herpes zoster 80.03 18.65 93 17759 108286 110463161
COVID-19 79.34 18.65 142 17710 244918 110326529
Renal failure 74.25 18.65 132 17720 226442 110345005
Stent placement 68.57 18.65 30 17822 7204 110564243
Secondary adrenocortical insufficiency 68.14 18.65 26 17826 4408 110567039
C-reactive protein abnormal 66.76 18.65 93 17759 129602 110441845
Symptom recurrence 66.28 18.65 26 17826 4746 110566701
Autoinflammatory disease 62.06 18.65 14 17838 367 110571080
Cellulitis 61.36 18.65 88 17764 125928 110445519
Tonsillitis 58.75 18.65 28 17824 8185 110563262
Influenza 57.28 18.65 100 17752 169001 110402446
Concomitant disease aggravated 55.54 18.65 34 17818 16330 110555117
Lymphadenopathy 52.58 18.65 58 17794 63777 110507670
Cellulitis staphylococcal 52.36 18.65 16 17836 1387 110570060
Drug interaction 52.14 18.65 9 17843 500174 110071273
Muscle abscess 51.63 18.65 16 17836 1453 110569994
Hepatosplenomegaly 47.70 18.65 23 17829 6896 110564551
Product supply issue 46.92 18.65 19 17833 3767 110567680
Actinomycotic sepsis 46.91 18.65 10 17842 200 110571247
Urticaria 46.84 18.65 135 17717 318722 110252725
Feeling abnormal 46.46 18.65 95 17757 180616 110390831
Chemokine increased 43.71 18.65 7 17845 24 110571423
Pneumonia streptococcal 41.50 18.65 17 17835 3472 110567975
Drug ineffective 41.48 18.65 400 17452 1520140 109051307
Cushingoid 41.46 18.65 25 17827 11687 110559760
Myocardial infarction 41.37 18.65 94 17758 191989 110379458
Hypertensive cardiomyopathy 40.75 18.65 10 17842 380 110571067
Joint swelling 39.81 18.65 159 17693 442686 110128761
Product use in unapproved indication 39.71 18.65 160 17692 447217 110124230
Arthralgia 39.21 18.65 237 17615 779395 109792052
Toxicity to various agents 38.04 18.65 15 17837 480540 110090907
Herpes zoster infection neurological 37.81 18.65 10 17842 514 110570933
Pneumonia 37.63 18.65 256 17596 876458 109694989
Pain 37.58 18.65 273 17579 954682 109616765
Varicella zoster virus infection 37.46 18.65 19 17833 6349 110565098
Oropharyngeal pain 37.01 18.65 73 17779 135203 110436244
Cough 36.98 18.65 160 17692 461481 110109966
Gastroenteritis 36.80 18.65 38 17814 38762 110532685
Secondary amyloidosis 36.77 18.65 9 17843 338 110571109
Disease recurrence 36.48 18.65 47 17805 60737 110510710
Nausea 35.83 18.65 93 17759 1235597 109335850
Familial mediterranean fever 35.82 18.65 8 17844 200 110571247
Steroid dependence 35.04 18.65 20 17832 8449 110562998
Synovitis 33.22 18.65 3 17849 274089 110297358
Drug ineffective for unapproved indication 32.47 18.65 59 17793 102779 110468668
Focal nodular hyperplasia 32.32 18.65 10 17842 903 110570544
Otitis media 31.86 18.65 18 17834 7458 110563989
Upper respiratory tract inflammation 31.56 18.65 15 17837 4356 110567091
Osteoporosis 31.41 18.65 53 17799 87099 110484348
Pharyngitis streptococcal 31.39 18.65 22 17830 13255 110558192
Short stature 30.61 18.65 10 17842 1077 110570370
Hypoaesthesia 29.91 18.65 7 17845 314216 110257231
Inflammatory marker increased 29.69 18.65 22 17830 14447 110557000
Blood lactate dehydrogenase increased 29.34 18.65 36 17816 44298 110527149
Chondrocalcinosis 28.22 18.65 11 17841 1974 110569473
Haemoglobin decreased 27.92 18.65 96 17756 248631 110322816
Hyperplasia 27.34 18.65 10 17842 1508 110569939
Spondyloarthropathy 26.74 18.65 10 17842 1604 110569843
Hyperferritinaemia 26.65 18.65 9 17843 1074 110570373
Vein disorder 26.46 18.65 15 17837 6255 110565192
Rhinorrhoea 26.40 18.65 54 17798 102612 110468835
Pericardial calcification 26.33 18.65 5 17847 54 110571393
Autoimmune thyroiditis 26.10 18.65 15 17837 6419 110565028
Systemic lupus erythematosus 25.57 18.65 5 17847 254333 110317114
Hand fracture 25.35 18.65 16 17836 8106 110563341
Dyspnoea 25.16 18.65 93 17759 1106779 109464668
SARS-CoV-2 test positive 24.56 18.65 21 17831 16914 110554533
Pharyngitis 24.56 18.65 25 17827 25073 110546374
Epidural lipomatosis 24.34 18.65 10 17842 2057 110569390
Viral infection 24.23 18.65 36 17816 53103 110518344
Drug resistance 24.02 18.65 37 17815 56337 110515110
Arthritis infective 24 18.65 17 17835 10412 110561035
Hypotension 23.56 18.65 30 17822 523819 110047628
Asteatosis 23.40 18.65 6 17846 273 110571174
Amyloidosis 23.23 18.65 11 17841 3170 110568277
Faecal calprotectin increased 22.90 18.65 14 17838 6705 110564742
General physical health deterioration 22.84 18.65 21 17831 425274 110146173
Cryopyrin associated periodic syndrome 22.78 18.65 7 17845 618 110570829
Lymph nodes scan abnormal 21.71 18.65 5 17847 144 110571303
Upper respiratory tract infection 21.61 18.65 58 17794 131270 110440177
Blood creatine phosphokinase decreased 21.30 18.65 8 17844 1299 110570148
Periodontal inflammation 21.16 18.65 4 17848 42 110571405
Subcutaneous abscess 21.01 18.65 15 17837 9302 110562145
Alopecia 20.81 18.65 17 17835 364736 110206711
Vitiligo 20.71 18.65 10 17842 3007 110568440
Vascular cognitive impairment 20.68 18.65 4 17848 48 110571399
Staphylococcal infection 20.66 18.65 39 17813 69905 110501542
Death 20.65 18.65 52 17800 698817 109872630
Peripheral swelling 20.48 18.65 21 17831 404013 110167434
Depression 20.44 18.65 13 17839 317322 110254125
Cutaneous symptom 20.39 18.65 7 17845 878 110570569
Infusion related reaction 20.25 18.65 19 17833 381143 110190304
Arthritis 19.96 18.65 66 17786 167520 110403927
Rash 19.83 18.65 211 17641 820753 109750694
Asthenia 19.79 18.65 52 17800 688947 109882500
Sleep disorder 19.76 18.65 4 17848 198640 110372807
Paraesthesia 19.71 18.65 10 17842 276511 110294936
Superinfection bacterial 19.70 18.65 9 17843 2392 110569055
Rheumatoid arthritis 19.68 18.65 12 17840 299601 110271846
Muckle-Wells syndrome 19.58 18.65 3 17849 7 110571440
Helicobacter infection 19.54 18.65 3 17849 181874 110389573
Inflammatory bowel disease 19.50 18.65 13 17839 7221 110564226
Gene mutation 19.50 18.65 10 17842 3419 110568028
Somnolence 19.41 18.65 12 17840 297437 110274010
Quality of life decreased 19.39 18.65 17 17835 14152 110557295
Abdominal discomfort 19.37 18.65 21 17831 393837 110177610
Fall 19.34 18.65 43 17809 603439 109968008
Graft versus host disease in gastrointestinal tract 19.22 18.65 14 17838 8954 110562493
Oedema peripheral 19.15 18.65 15 17837 328645 110242802
Overdose 18.97 18.65 7 17845 233787 110337660
Epstein-Barr virus infection 18.95 18.65 19 17833 18719 110552728
Ileal ulcer 18.74 18.65 8 17844 1809 110569638
Obliterative bronchiolitis 18.72 18.65 10 17842 3713 110567734

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AC08 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Interleukin inhibitors
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35842 antirheumatic drug
CHEBI has role CHEBI:35845 gout suppressant
CHEBI has role CHEBI:38070 anti-arrhythmia drug
CHEBI has role CHEBI:66981 ophthalmology drug
CHEBI has role CHEBI:67079 anti-inflammatory agent
CHEBI has role CHEBI:75835 anti-anaemic agent
CHEBI has role CHEBI:76916 hyperglycemic agent
CHEBI has role CHEBI:145947 antiatherosclerotic agent

Related Drugs by ATC class:

L04AC Interleukin inhibitors 18 drugs
anakinrabasiliximabbimekizumabbrodalumabdaclizumabguselkumabixekizumabmirikizumabrilonaceptrisankizumabsarilumabsatralizumab show all 18 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Familial Mediterranean fever indication 12579009 DOID:2987
Articular gout indication 48440001 DOID:13189
Deficiency of mevalonate kinase indication 124327008 DOID:0050452
Systemic onset juvenile chronic arthritis indication 201796004
TNF receptor-associated periodic fever syndrome (TRAPS) indication 403833009
Cryopyrin associated periodic syndrome indication 430079001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Interleukin-1 beta Cytokine ANTIBODY BINDING DRUG LABEL DRUG LABEL

External reference:

IDSource
D09315 KEGG_DRUG
4028805 VUID
N0000178497 NUI
4028805 VANDF
CHEBI:749608 CHEBI
CHEMBL1201834 ChEMBL_ID
C541220 MESH_SUPPLEMENTAL_RECORD_UI
6773 IUPHAR_LIGAND_ID
DB06168 DRUGBANK_ID
853491 RXNORM
165731 MMSL
26503 MMSL
d07451 MMSL
013212 NDDF
698091001 SNOMEDCT_US
703376008 SNOMEDCT_US
C2718773 UMLSCUI
8836 INN_ID
37CQ2C7X93 UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ilaris HUMAN PRESCRIPTION DRUG LABEL 1 0078-0734 INJECTION, SOLUTION 150 mg SUBCUTANEOUS BLA 32 sections